Below are the most recent publications written about "Atenolol" by people in Profiles.
-
Selamet Tierney ES, Levine JC, Sleeper LA, Roman MJ, Bradley TJ, Colan SD, Chen S, Campbell MJ, Cohen MS, De Backer J, Heydarian H, Hoskoppal A, Lai WW, Liou A, Marcus E, Nutting A, Olson AK, Parra DA, Pearson GD, Pierpont ME, Printz BF, Pyeritz RE, Ravekes W, Sharkey AM, Srivastava S, Young L, Lacro RV. Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. Am J Cardiol. 2018 05 01; 121(9):1094-1101.
-
Selamet Tierney ES, Levine JC, Chen S, Bradley TJ, Pearson GD, Colan SD, Sleeper LA, Campbell MJ, Cohen MS, De Backer J, Guey LT, Heydarian H, Lai WW, Lewin MB, Marcus E, Mart CR, Pignatelli RH, Printz BF, Sharkey AM, Shirali GS, Srivastava S, Lacro RV. Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr. 2013 Jun; 26(6):657-66.
-
Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008 Dec; 52(6):1022-9.
-
Matsui Y, Eguchi K, Shibasaki S, Ishikawa J, Hoshide S, Pickering TG, Shimada K, Kario K. Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study. J Hypertens. 2008 Oct; 26(10):1928-34.
-
Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008 Aug; 156(2):241-7.
-
Medei EH, Nascimento JH, Pedrosa RC, Barcellos L, Masuda MO, Sicouri S, Elizari MV, de Carvalho AC. Antibodies with beta-adrenergic activity from chronic chagasic patients modulate the QT interval and M cell action potential duration. Europace. 2008 Jul; 10(7):868-76.
-
Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006 Feb 07; 47(3):547-51.
-
Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahl?f B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol. 2005 Dec 01; 96(11):1530-6.
-
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
-
Schubiger JL, Wohler D, Gr?ne S, Weisser B, Kraft K, Del Bufalo A, Binswanger B, Mengden T, Sp?hler T, Greminger P, et al. [Are home blood pressure measurements and 24-hour ambulatory recordings superior to office measurements? Comparison of 3 blood pressure recording methods in a study of cilazapril versus atenolol]. Schweiz Rundsch Med Prax. 1993 May 18; 82(20):587-92.